Can This Patient Be on Both Aspirin and Xarelto?
Yes, this patient with persistent atrial fibrillation and peripheral arterial stenosis can and likely should be on both aspirin and rivaroxaban (Xarelto), but only if they are not at high bleeding risk. This combination addresses both stroke prevention from AF and reduces major adverse cardiovascular and limb events from PAD.
The Evidence-Based Approach
For the Atrial Fibrillation Component
The 2024 ESC AF guidelines are clear: antiplatelet drugs should NOT be used as an alternative to oral anticoagulation for stroke prevention in AF 1. Your patient needs full-dose anticoagulation (rivaroxaban 20 mg daily for AF, or 15 mg if CrCl 30-49 mL/min) for stroke prevention—this is non-negotiable.
The guidelines explicitly state that combining antiplatelet drugs with anticoagulants should only occur in selected patients with acute vascular disease, and that adding antiplatelet treatment to anticoagulation is not recommended (Class III) to prevent recurrent embolic stroke 1.
For the Peripheral Arterial Disease Component
However, the 2024 ACC/AHA PAD guidelines present a different picture. When PAD coexists with an indication for full-intensity anticoagulation (like AF), adding single antiplatelet therapy is reasonable (Class IIa recommendation) 2. This is specifically addressed in their recommendations.
The guidelines note that rivaroxaban 2.5 mg twice daily plus low-dose aspirin is effective for PAD to reduce major adverse cardiovascular events (MACE) and major adverse limb events (MALE) 2. However, this low-dose rivaroxaban regimen was studied in patients WITHOUT an indication for full anticoagulation—those patients were excluded from the COMPASS trial 1.
The Clinical Decision Algorithm
Here's how to proceed:
Start with full-dose rivaroxaban for AF (20 mg daily, or 15 mg if CrCl 30-49)
- This is mandatory for stroke prevention
Assess bleeding risk carefully:
- History of major bleeding?
- Age >75 with other risk factors?
- Renal impairment (CrCl <30 contraindicates this combination)?
- Concurrent medications increasing bleeding risk?
- Recent hemorrhagic or lacunar stroke?
If NOT at high bleeding risk, ADD low-dose aspirin (81 mg daily)
If at HIGH bleeding risk:
- Use full-dose rivaroxaban alone
- Do NOT add aspirin—the bleeding risk outweighs benefit 4
Critical Caveats and Monitoring
The bleeding risk is real and significant. Recent meta-analyses show that rivaroxaban plus aspirin increases major bleeding risk (HR 1.41-1.54) compared to aspirin alone 5, 6. One 2026 study found major bleeding rates of 5.74 per 100 patient-years with combination therapy versus 1.37 with DOAC monotherapy in AF patients 4.
What you're NOT doing: You are NOT using the low-dose rivaroxaban 2.5 mg twice daily regimen studied in COMPASS. That regimen is for PAD patients without AF. Your patient needs full anticoagulation for AF, so you use full-dose rivaroxaban PLUS aspirin if bleeding risk permits.
Monitor closely for:
- Any bleeding (GI, urinary, intracranial)
- Hemoglobin drops
- Renal function changes (adjust rivaroxaban dose accordingly)
- Drug interactions (avoid carbamazepine and other strong CYP3A4 inducers that reduce rivaroxaban levels) 7
The Bottom Line
Use full-dose rivaroxaban (for AF) plus low-dose aspirin 81 mg (for PAD) if bleeding risk is acceptable 2. This dual-pathway approach addresses both conditions but requires careful patient selection and monitoring. If bleeding risk is prohibitive, prioritize the full-dose anticoagulation for AF alone, as stroke prevention takes precedence over limb event reduction in this clinical scenario.
The combination is supported by PAD guidelines specifically for patients requiring full anticoagulation 2, though the AF guidelines are more conservative about adding antiplatelets 1. The key is individualized bleeding risk assessment—if HAS-BLED score is ≥3 or prior major bleeding, strongly consider rivaroxaban monotherapy.